IDEXX Laboratories Inc. (NASDAQ: IDXX) is -43.79% lower on its value in year-to-date trading and has touched a low of $318.50 and a high of $706.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IDXX stock was last observed hovering at around $366.06 in the last trading session, with the day’s gains setting it 4.08% off its average median price target of $515.00 for the next 12 months. It is also 47.12% off the consensus price target high of $700.00 offered by 12 analysts, but current levels are 15.88% higher than the price target low of $440.00 for the same period.
Currently trading at $370.14, the stock is 4.09% and 1.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.47 million and changing 1.11% at the moment leaves the stock -28.32% off its SMA200. IDXX registered -43.70% loss for a year compared to 6-month loss of -33.26%.
The stock witnessed a 12.51% gain in the last 1 month and extending the period to 3 months gives it a -27.23%, and is -2.20% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.49% over the week and 3.52% over the month.
IDEXX Laboratories Inc. (IDXX) has around 10350 employees, a market worth around $30.75B and $3.27B in sales. Current P/E ratio is 43.44 and Fwd P/E is 35.53. Profit margin for the company is 22.40%. Distance from 52-week low is 16.21% and -47.64% from its 52-week high. The company has generated returns on investments over the last 12 months (48.00%).
IDEXX Laboratories Inc. (IDXX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for IDEXX Laboratories Inc. (IDXX) is a “Overweight”. 12 analysts offering their recommendations for the stock have an average rating of 2.20, where 4 rate it as a Hold and 2 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
IDEXX Laboratories Inc. is expected to release its quarterly report on 11/01/2022.The EPS is expected to grow by 28.30% this year.
IDEXX Laboratories Inc. (IDXX) Top Institutional Holders
The shares outstanding are 84.41M, and float is at 83.22M with Short Float at 2.38%.
IDEXX Laboratories Inc. (IDXX) Insider Activity
A total of 69 insider transactions have happened at IDEXX Laboratories Inc. (IDXX) in the last six months, with sales accounting for 11 and purchases happening 58 times. The most recent transaction is an insider sale by AYERS JONATHAN W,the company’sDirector. SEC filings show that AYERS JONATHAN W sold 250 shares of the company’s common stock on Feb 15 at a price of $509.70 per share for a total of $0.13 million. Following the sale, the insider now owns 0.63 million shares.
IDEXX Laboratories Inc. disclosed in a document filed with the SEC on Nov 29 that POLEWACZYK JAMES F (Executive Vice President) sold a total of 4,595 shares of the company’s common stock. The trade occurred on Nov 29 and was made at $633.00 per share for $2.91 million. Following the transaction, the insider now directly holds 14818.0 shares of the IDXX stock.
Still, SEC filings show that on Nov 12, MCKEON BRIAN P (Executive VP & CFO) disposed off 9,225 shares at an average price of $620.73 for $5.73 million. The insider now directly holds 26,317 shares of IDEXX Laboratories Inc. (IDXX).
IDEXX Laboratories Inc. (IDXX): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 5.86% up over the past 12 months and Medtronic plc (MDT) that is -28.91% lower over the same period. Boston Scientific Corporation (BSX) is -10.93% down on the 1-year trading charts.